Related references
Note: Only part of the references are listed.A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma
Guanghui Gao et al.
ACTA ONCOLOGICA (2010)
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma
Anastasios Chatzitolios et al.
ANNALS OF HEMATOLOGY (2010)
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
Heidi Nyman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP
Moo-Kon Song et al.
LEUKEMIA & LYMPHOMA (2009)
Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas
Semra Paydas et al.
LEUKEMIA RESEARCH (2008)
Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation
I. S. van Houdt et al.
HISTOPATHOLOGY (2007)
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence
David B. Seligson et al.
CLINICAL CANCER RESEARCH (2007)
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
Kenneth S. Wilson et al.
LEUKEMIA & LYMPHOMA (2007)
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome
Y Kojima et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
FAS death domain deletions and cellular FADD-like interleukin 1β converting enzyme inhibitory protein (long) overexpression:: Alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes
Hidenobu Takahashi et al.
CLINICAL CANCER RESEARCH (2006)
Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma
Latha Shivakumar et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma
B Eser et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy
G Valente et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Prognostic biomarkers in diffuse large B-cell lymphoma
IS Lossos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma
Jettle J. F. Muris et al.
HEMATOLOGICAL ONCOLOGY (2006)
State-of-the-art therapeutics: Diffuse large B-cell lymphoma
B Coiffier
JOURNAL OF CLINICAL ONCOLOGY (2005)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes
R Watanuki-Miyauchi et al.
PATHOLOGY INTERNATIONAL (2005)
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas
JJF Muris et al.
BLOOD (2005)
Survivin splice variants regulate the balance between proliferation and cell death
H Caldas et al.
ONCOGENE (2005)
Impairment of death-inducing signalling complex formation in CD95-resistant human primary lymphoma B cells
A Lajmanovich et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Building an outcome predictor model for diffuse large B-cell lymphoma
AI Sáez et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis
I Tamm et al.
HEMATOLOGY JOURNAL (2004)
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma
EJ Schlette et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
DW Chang et al.
EMBO JOURNAL (2002)
Dysregulation of apoptosis genes in hematopoietic malignancies
S Kitada et al.
ONCOGENE (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
SL Barrans et al.
BLOOD (2002)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line
M Irisarri et al.
LEUKEMIA (2000)
Mitochondrial control of cell death
G Kroemer et al.
NATURE MEDICINE (2000)
Share Paper
